EMEA-001904-PIP02-17

Key facts

Active substance
Brincidofovir
Therapeutic area
Infectious diseases
Decision number
P/0348/2018
PIP number
EMEA-001904-PIP02-17
Pharmaceutical form(s)
  • Oral suspension
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of adenovirus in immunocompromised patients
Route(s) of administration
Oral use
Contact for public enquiries
SymBio Pharmaceuticals Limited

E-mail: mkano.mk11@symbiopharma.com
Tel. +818039323354

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating